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7LETTER TO THE EDITOR
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mThis is to respond to the letter by John T. Slattery,
hD, entitled “Intravenous versus oral busulfan—per-
aps not as different as suggested,” [1] which was
ublished in the April 2003 issue of BBMT. In his
etter, Dr. Slattery discussed 3 of our articles on the
se of intravenous (IV) busulfan (Bu) as a preparative
egimen for pre–bone marrow transplantation ther-
py that were published in BBMT during 2002 [2-4].
We agree with Dr. Slattery that IV Bu has a place
n hemopoietic stem cell transplantation and that IV
ather than oral administration decreases liver expo-
ure to Bu, which may contribute to a decreased risk
or veno-occlusive disease. However, we think that
everal points raised by Dr. Slattery bear clariﬁcation.
n reference to Kashyap et al. [2], who compared the
utcomes of 30 patients who received oral Bu 1 mg/kg
t City of Hope (oral-reference group) with those of
1 patients who received IV Bu 0.8 mg/kg at City of
ope and other centers (IV-other), Dr. Slattery states,
Unfortunately, the comparison failed to account for
ifferences in Bu area under the plasma concentra-
ion–time curve (AUC).” This is true; AUC data were
ot available on the 30 oral Bu patients, so a statistical
omparison of AUC values was not possible.
Dr. Slattery provides his own comparisons of var-
ous AUC values, including both peak and steady
tate, associated with oral Bu 1 mg/kg to those asso-
iated with IV Bu 0.8 mg/kg. He cites “a mean AUC
f 1350-1400 M  min. . .” from his own work, pro-
iding a computation apparently based on a determin-
stic mathematical model relating oral Bu dose to
lood concentrations over time. He compares a hypo-
hetical concentration exposure value associated with a
resumed 60- to 90-min absorption of 1 mg/kg oral
u so obtained with the median IV Bu systemic peak
lasma concentration reported by Andersson et al. [4]
nd concludes that there is little difference between
ither the peak or the steady-state AUC values of the
Bu delivery modes. Dr. Slattery notes various com-
licating factors that are not accounted for by his
omputations. Additionally, he provides a detailed ex-
lanation of this “relatively small difference between
ral vs. IV peak concentration experienced by the
iver,” which he implicitly assumes as fact in conse-
uence of earlier hypothetical computations. His ex-
lanation relies on some toxicologic reasoning in
hich the distinction between putative underlying p
22mpirical results and hypothetical mathematical com-
utations is unclear, at least to us.
The toxicologic and mathematical complexities
nvolved in assessing the Bu delivered dose as a func-
ion over time after either oral or IV dosing are sub-
tantial, and in this area Dr. Slattery is a well-recog-
ized expert. We do not presume to argue toxicologic
ssues. Our primary concern is clinical outcome, and
he statistical issues in interpreting the clinical data in
he manuscript by Kashyap et al. [2] are less complex,
ecause these data simply relate the numbers of pa-
ients experiencing veno-occlusive disease, dying of
eno-occlusive disease, and dying in general within
he 2 groups described previously. Each comparison
hows that the serious adverse event rate for the 30
ral-reference patients is higher than that of the 61
V-other patients. All 3 comparisons are statistically
igniﬁcant. Although there is redundancy in these
omparisons because of overlapping events, it is evi-
ent from the data that, on average, the IV-other
atients had substantively better outcomes than the 30
ral-reference patients. An important issue is that the
1 patients were not randomized between oral and IV
u, so the observed differences in patient outcomes
ould be (partly) explained by confounding factors,
ncluding treatment center and latent variables. Given
hese considerations, however, it seems likely that a
atient contemplating allogeneic transplantation, after
nspecting these data, would choose IV over oral Bu
ven without formal statistical analysis.
If one assumes that Dr. Slattery’s conclusion of
ubstantive equivalence in delivered dose to the liver
etween the 2 formulations is correct, then the essen-
ial issue remains of explaining why the IV Bu patients
ad such comparatively better outcomes in this par-
icular set of 91 patients. This, again, raises the ques-
ion of whether a patient would choose oral over IV
u on the basis of Dr. Slattery’s discussion of AUC
alues and peak concentrations and given the adverse
vent data reported by Kashyap et al. [2]. The basic
ssue here is that of making clinical decisions on the
asis of surrogate intermediate end points rather than
n observed clinical outcome data.
Another issue that was raised by Dr. Slattery is the
nterpretation of the survival time data of 36 chronic
yelogenous leukemia patients given IV BuCy2 as aioavailability and Patient
oi:10.1016/j.bbmt.2003.09.001nefitreparative regimen [3]. Statistically, because this is a
small data set of patients who were all given the same
preparative regimen, inferentially it can be at most
suggestive. However, the data do have the interesting
feature that, on estimating the hazard of death (11 of
the 36 patients died, and the remaining 25 were ad-
ministratively censored) as a function of steady-state
AUC, there was a pronounced U shape, indicating
that the death rate was lowest in a middle range of
AUC values. As we concluded, “These results suggest
that precise Bu delivery may be even more important
than previously thought not only in relation to regi-
men-related toxicity, but also in the development of
clinically relevant aGVHD and for the likelihood of
being alive beyond 1 year after HSCT . . . a general
conclusion is that an optimal range of AUC values
likely does exist.” Of course, this range cannot be
precisely identiﬁed either on the basis of data from
only 36 patients or on the basis of nonclinical data.
We maintain that IV dosing always gives more
precise control of systemic drug exposure. The
pharmacokinetic (PK) variability of oral Bu led to
discovery of the important relationships between
PK and both toxicity and engraftment [5-9]. Indeed,
such variable drug bioavailability has also led to the
recommendation that drugs should be administered
IV when accuracy of dosing and rapidity of action
are important [10]. Without exception, PK accuracy
is always superior for IV compared with orally ad-
ministered drugs. As a logical extension, monitoring
PK parameters of the initial dose of IV Bu and
performing an adjustment of the remaining doses
produces more accurate Bu delivery than even daily
monitoring with repeated dosage adjustments of
oral Bu. Repeated sampling is impractical and awk-
ward because of the logistics involved in shipping
and subsequent analyses in all but very few trans-
plant centers with a close-by Bu-PK laboratory.
Additionally, labor-intensive repeated sample ship-
ments and laboratory consulting charges that often
exceed US $1000 per sample set (data from the
busulfan pharmacokinetics laboratory of the Seattle
Cancer Care Alliance) rapidly increase the appeal of
IV Bu in times of increasing constraints on health-
care expenditures.
Finally, in comparing oral with IV Bu dosing, such
a comparison should be based exclusively on oral drug
bioavailability. The oral bioavailability may not be
estimated reliably from a clinical study of patients who
received only 1 (oral) Bu formulation. This is espe-
cially true when dosing algorithms are vague and un-
speciﬁed beyond “1 mg/kg.” Oral drug bioavailability
is best determined by comparing the systemic expo-
sure, AUC, achieved after an oral dose with that after
an IV dose (100% bioavailability) in the same patients
by using the same drug and same dosing algorithm
[11-17]. This method to determine oral Bu bioavail-
ability has been used by 3 groups using 3 different IV
Bu solutions with 100% bioavailability [18-20]. All 3
groups arrived at the common conclusion that the
bioavailability of oral Bu is 70% to 80% (Table 1).
Collectively, these reports establish that an appropri-
ate IV Bu dose to substitute for an oral 1 mg/kg dose
is 0.7 to 0.8 mg/kg. The higher-dose equivalent, 0.8
mg/kg, was used in our phase II study of IV Bu [4].
On the basis of these data, we consider it essen-
tially unarguable that IV Bu provides superior dosing
accuracy compared with the oral formulation, both
with regard to initial dose delivery and in effectively
controlling interdose variability in systemic exposure.
The latter is simply not attainable with oral Bu, which
is highly variable with regard to systemically deliv-
ered—that is, bioavailable—drug, both with respect to
patient-to-patient variability and, more importantly,
also in how systemic exposure varies from 1 dose to
the next in the same patient [21]. The importance of
the improved dose delivery obtained with IV Bu is the
subject of ongoing and planned studies with the new
formulation.
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Table 1. Bioavailability of Oral Busulfan Assessed against an IV
Reference Dose*
Investigators
IV Dose and
Solvent System*
Oral
Dose
Oral
Bioavailability,
% (Range)
Hassan et al.
[18]
2 mg total
dose, PG/
Ethanol/DMSO
2 mg Pediatric:
68 (22-120)
Adult: 80 (47-103)
Schuler et al.
[19]
0.5-0.6 mg/kg,
DMSO
1 mg/kg 70 (44-94)
Andersson
et al. [20]
0.8 mg/kg, DMA/
PEG400
1 mg/kg 69 (<10 to 100)
Average
(adult only)
74 (<10 to 103)†
PG indicates propylene glycol; DMSO, dimethylsulfoxide; DMA,
N, N-dimethylacetamide; PEG400, polyethyleneglycol-400.
*These solvent systems provide 100% bioavailability for dissolved
busulfan when administered IV, on the basis of extraction and
recovery of Bu in the respective formulations.
†The maximum ranges of oral bioavailability calculated in the
respective articles.
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